Brief: Oryzon Receives Russian Patent For Vafidemstat Until At Least 2040
Dec 2 (Reuters) - Oryzon Genomics SA ORY.MC :
* CONTINUES TO STRENGTHEN ITS PATENT PORTFOLIO FOR
VAFIDEMSTAT
* PATENT ISSUED BY RUSSIAN PATENT OFFICE RELATES TO
VAFIDEMSTAT
* ONCE GRANTED, RUSSIAN PATENT WILL NOT EXPIRE UNTIL AT
LEAST 2040
* PATENT APPLICATIONS ARE ALSO PENDING IN OTHER RELEVANT
MARKETS
Source text: https://tinyurl.com/444647vp
Further company coverage: ORY.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28